PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. The company develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its lead product candidate is PDS0101, a monotherapy first line therapy for cervical intraepithelial neoplasia of cancer. In addition, the company develops PDS0102, which is in phase 2 clinical trial for treatment of prostate and breast cancers. Further, its pipeline product portfolio includes PDS0103 for treatment of colorectal, breast, ovarian, and lung cancers; and PDS 0104 for treatment of melanoma. Additionally, the company offers Versamune, a T-cell activating platform developed for immunotherapy approaches, such as checkpoint inhibitors, CAR-T cells and live-vector based vaccines, etc. The company has collaboration agreement with Merck and Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer. PDS Biotechnology Corporation was incorporated in 2009 and is based in Berkeley Heights, New Jersey.